NCT03395873View on ClinicalTrials.gov

Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy

PHASE1TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 29, 2018

Primary Completion Date

May 15, 2019

Study Completion Date

May 15, 2019

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Avelumab

"* Decitabine 20mg/m2 IV day 1-5, every 28 days~* Avelumab 10mg/kg IV, day 1, every 14 days"

Trial Locations (1)

17033

Penn State Cancer Institute, Hershey

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Milton S. Hershey Medical Center

OTHER

NCT03395873 - Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy | Biotech Hunter | Biotech Hunter